Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials
CONCLUSIONS: Treatment with an SGLT2i resulted in consistent and significant improvements in health status for both Black and White patients with heart failure.PMID:37191040 | DOI:10.1161/CIRCULATIONAHA.122.063263
Source: Circulation - Category: Cardiology Authors: Kashvi Gupta John A Spertus Mary Birmingham Kensey L Gosch Mansoor Husain Dalane W Kitzman Bertram Pitt Sanjiv J Shah James L Januzzi Ildiko Lingvay Javed Butler Mikhail Kosiborod David E Lanfear Source Type: research
More News: Canagliflozin | Cardiology | Cardiomyopathy | Cardiovascular | Clinical Trials | Dapagliflozin | Forxiga | Heart | Heart Failure | Invokana | Sodium | Study | USA Health